ATAI News and Press, ATAI Life Sciences N.V. From 02/12/24

2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...

2024-02-06 17:11:46 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value Read the full article on Seeking Alpha For further d...

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August ...

A recent influx in psychedelic-related research has revealed that some classic psychedelic drugs have the potential to offer long-term relief against several mental disorders. The expanding scientific literature states that psychedelics such as LSD, psilocybin (magic mushrooms) and ayahuasca ...

Researchers from the University of Split’s Medical School’s Department of Medical Humanities recently used computerized linguistic tools to gain insight into online reports of mystical psychedelic experiences. The scientists found that intense psychedelic experiences tend to be ...

2024-01-24 09:00:41 ET Palm Beach, FL – January 24, 2024 – FN Media Group News Commentary – The coming years could see a massive shift in the U.S. government’s approach to regulating hallucinogenic drugs. Several biopharma companies are developing psy...

A recent study has suggested that psychedelics may deliver their antidepressive effects by “shaking up” the brain networks responsible for regulating emotion. Major advances in psychedelic research have revealed that classic psychedelics have the potential to treat various mental...

2024-01-09 13:56:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there’s still tremendous research and insight happening beneath the surface. Even Elon Mu...

2024-01-09 12:00:00 ET Summary Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year. Alex Carchidi shares why Compass Pathways, Cybin, and Atai are the most promising companies for in...

2024-01-09 08:35:20 ET BT Brands  ( BTBD ) +135% . Sentage Holdings ( SNTG ) +95% . Juniper Networks  ( JNPR ) +23% jumps 25% on report HPE is nearing buyout deal. Syra Health  ( SYRA ) +17% . Elicio Therapeutics  ( ELT...